FDA Alerts

The FDA has approved Jardiance (empagliflozin) for the reduction of risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.

The FDA has approved the expansion of the age indication for FluLaval Quadrivalent.

The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.

The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.

The FDA makes its website accessible for the widest possible audience to get up to date information and alerts.

The FDA approved the Amplatzer PFO Occluder device to reduce stroke risk in patients who have had a stroke from a blood clot passing through a patent foramen ovale.

The FDA has approved class-wide labeling changes for all prescription testosterone products with information regarding the risks of abuse and dependence.

The FDA approved a new method of administering treatment for patients with wet age-related macular degeneration and macular edema following retinal vein occlusion.

The FDA has approved a quadrivalent formulation of Flublok influenza vaccine, which protects against 4 strains of influenza.

The FDA has approved Zubsolv (buprenorphine/naloxone CIII sublingual tablets) 0.7mg/0.18mg for the treatment of patients with opioid dependence.